AiPharma sells assets to Aditxt

AiPharma, a Malaysian company discovering, developing and commercialising antiviral therapies across a broad spectrum of infectious diseases, has entered a binding agreement to sell all of its assets to Aditxt.

Based in Richmond, Virginia, Aditxt is a biotech innovation company with a mission to improve the health of the immune system.

AiPharma holds directly, or through its affiliates worldwide (excluding Japan), exclusive rights to Avigan/Reeqonus / Qifenda and all formulations of favipiravir, a broad spectrum oral antiviral drug that targets COVID-19 and other infectious diseases.

The agreement follows Aditxt’s prior announcement on August 25, 2021 to acquire the company and Aditxt’s funding of a bridge loan to AiPharma, a key term toward completion of the acquisition, subject to certain closing conditions.

The acquisition will form a business segment for Aditxt that is focused on the prevention, treatment, and monitoring of infectious diseases.

Dr Alessandro Gadotti, CEO of AiPharma Group commented, “We believe that the combination of Aditxt and AiPharma is uniquely positioned to address the key topics of the COVID-19 pandemic, starting from monitoring of immune status and outpatient treatment for the illness.

“We have treated in excess of 1.5 million patients with our antiviral tablets. The strength of oral antiviral treatments such as Avigan/Reeqonus in real terms is that they fight COVID-19 in the community and not in hospitals – which can significantly reduce pressures on healthcare systems.

“Our joint product portfolio puts us on the front line in the fight against COVID-19 and future pandemic preparedness.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news